Ulipristal Tablets

Mechanism

Ulipristal modulates progesterone receptors, delaying ovulation and preventing fertilization in emergency contraception. In fibroid therapy, it reduces fibroid volume and controls bleeding by altering progesterone activity in uterine tissue.

Pharmacokinetics

• Absorption: Rapid oral absorption.
• Distribution: Highly protein bound.
• Metabolism: Hepatic metabolism via CYP3A4.
• Elimination: Excreted in feces and urine.
• Half-life: ~32 hours (30 mg dose).

Side Effects

• Headache
• Abdominal pain
• Nausea
• Dizziness
• Menstrual cycle changes
• Rare: liver injury (fibroid therapy)

Contraindication

• Known or suspected pregnancy
• Severe hepatic impairment
• Hypersensitivity to Ulipristal or excipients

Interaction

• CYP3A4 inducers: Rifampicin, carbamazepine, St. John’s wort reduce efficacy.
• Hormonal contraceptives: Starting progestin too soon may impair Ulipristal’s effect.
• Other emergency contraceptives: Do not combine with levonorgestrel in same cycle.

Warning and Precautions

• Evaluate for ectopic pregnancy if severe abdominal pain occurs post-use.
• Menstrual cycle may be delayed; rule out pregnancy if >1 week late.
• Barrier contraception advised until next menses.
• Monitor liver function during fibroid therapy.